Fifty 410 vs. Hims & Hers: prices, fine print, and the honest verdict

Tirzepatide pricing

Fifty 410 advertises tirzepatide from $133/mo but publishes no maintenance-dose figure, so it can't be ranked on the all-in basis — the honest label is “starting price only.” Hims & Hers offers tirzepatide without a published price we could capture.

Different products, not just different prices

Hims & Hers fulfills the FDA-approved product — reviewed manufacturing, verified identity and sterility, stable legal status — while Fifty 410 sells compounded medication: pharmacy-prepared, not FDA-reviewed, and operating under the narrower post-shortage pathways our legal guide tracks. The compounded discount is partly a risk premium; whether it's worth taking depends on the pharmacy behind it and your tolerance for regulatory turbulence.

Transparency

Fifty 410: Source-verified (verified 2026-08-05); dispensing pharmacy not publicly named. Hims & Hers: No price published (verified 2026-08-05); names its pharmacy — brand fulfillment; compounded program closed to new patients. In this market, a named pharmacy and a dated, source-verified price are worth real money — they are what let you check the claim instead of trusting it.

Commitment & cancellation

Fifty 410: unknown; not published. Hims & Hers: plan recurs; plan recurs until cancelled.

Two ladders, side by side

The 2.5-to-10 mg climb is the honest stress test: Fifty 410 publishes only the $133 starting rung — the upper ladder is unpriced. A flat ladder makes dose decisions purely clinical; a scaled one attaches an invoice to every escalation — including the post-plateau bump from 10 to 12.5 mg that many patients eventually face. Full framework: the titration cost guide.

The five normalizations, applied to this pair

1 · All-in, not advertised. Fifty 410 publishes no figure to normalize; Hims & Hers bills at manufacturer/insurance rates plus any stated program fee. 2 · Maintenance basis. Fifty 410 publishes only a starter figure ($133), which this normalization exists to catch. 4 · Evidence tiered. Fifty 410: source-verified, read 2026-08-05; Hims & Hers: no price published, read 2026-08-05. 5 · Pharmacy weighed. Fifty 410 names no pharmacy; Hims & Hers names brand fulfillment; compounded program closed to new patients — in a pharmacy-variance market, disclosure is a scored asset. Run the same five on any roundup you read and most published “cheapest” lists reorder themselves.

Fine print, itemized

Fifty 410: no membership — the medication figure is the billed figure; not published; commitment: unknown. Hims & Hers: no membership — the medication figure is the billed figure; plan recurs until cancelled. The pattern to police on both sides is the same: memberships that outlive the medication order, renewal-relative cancellation deadlines, and prepaid terms whose refund language matters more than their discount in a year of live litigation. Cancel in writing; screenshot everything.

Transparency, audited

Fifty 410 carries source-verified pricing (last read 2026-08-05); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Hims & Hers carries no price published pricing (last read 2026-08-05); pharmacy disclosure is its strong suit — brand fulfillment; compounded program closed to new patients, brand fulfillment. Our weighting is unapologetic: in a market of identical molecule names, a dated source-verified price and a named pharmacy are the two claims a buyer can actually check, and they carry 25 of 100 formula points between them — the methodology shows the math, and the pharmacy guide decodes every answer the five questions can return.

Switching between them

Neither program locks the door: a Fifty 410-to-Hims & Hers move is a new intake, a new prescription at the new pharmacy, and a written cancellation at the old shop — typically a one-to-two-week overlap if you time the last fill. What does not move with you: prepaid months, membership balances, and any dose paperwork, so re-state your current rung clearly at the new intake.

Refills, shipping, and the week-to-week reality

Past the pricing page, the operational facts are what a subscriber lives with: Fifty 410: shipping unknown; consultation unknown. Hims & Hers: shipping included; consultation included in plan; async visit model. Cold-chain shipments run 3–7 days across the market; the recurring failure modes are refill-timing gaps and pharmacy backlogs, so whichever program wins here, order refills a week early and confirm the pharmacy’s current turnaround at intake.

Who should pick which

Pick Fifty 410 if its published terms happen to fit your state, format, or timing. Pick Hims & Hers if a named pharmacy is non-negotiable for you; only the FDA-approved product will do. Neither answer is universal — which is the argument for choosing from data with dates on it rather than from whichever ad loaded first.

What verification would take

For Fifty 410, ranking would require: any published price at all, on a page we can capture and date; the dose structure (flat or scaled, with the 10 mg tier stated); the pharmacy's name, 503A/503B status, and state licensure; commitment and cancellation terms verbatim. For Hims & Hers, ranking would require: any published price at all, on a page we can capture and date; the dose structure (flat or scaled, with the 10 mg tier stated); the pharmacy's name, 503A/503B status, and state licensure; commitment and cancellation terms verbatim. We publish the checklist because the gap is fixable — providers that clear it get ranked on the same arithmetic as everyone else, and readers who ask these questions get the answers this page can't yet print.

If neither one fits

Two programs never exhaust the market — the nearest substitutes on the verified board are NexLife at $215 (flat, no membership, named pharmacy); Yucca Health at $258 (flat, no membership); IVIM Health at $278 (dose-scaled, $75 membership included) — or skip straight to the rankings page, where every standard “cheapest / best / no-commitment” question is answered in one sourced sentence.

The verdict

This one is a product decision more than a price decision — cheapest-possible compounded versus FDA-approved brand. Both records, with dates and sources, live in the pricing database.